SOPHiA GENETICS CFO sells 774 shares at $8.33

SOPHiA GENETICS’ CFO sold a small number of shares to cover taxes from RSU vesting under a pre-set Rule 10b5-1 plan.

Rhea-AI Filing Summary

SOPHiA GENETICS SA (SOPH) reported that Chief Financial Officer George Cardoza sold 774 ordinary shares on September 21, 2026 at $8.33 per share, leaving him with 308,318 shares held directly. The footnote states these shares were sold in the open market solely to cover tax withholding obligations from restricted stock units that vested on September 18, 2026, under a pre-established Rule 10b5-1(c) trading plan, and that the trades were not discretionary.

Insider Trade Summary 10b5-1

Net Seller: 774 shares

Net Sell 1 txn

Insider CARDOZA GEORGE

Role Chief Financial Officer

Sold 774 shs ($6K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares F1	774	$8.33	$6K

Holdings After Transaction: Ordinary Shares — 308,318 shares (Direct)

Footnotes (1)

1. F1. Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on September 18, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1(c) trading plan adopted by the Reporting Person and do not represent discretionary trades.

Key Figures

Shares sold: 774 shares Sale price: $8.33 per share Shares held after transaction: 308,318 shares +1 more

4 metrics

Shares sold 774 shares Ordinary shares sold by the CFO on September 21, 2026

Sale price $8.33 per share Price for the 774 ordinary shares sold

Shares held after transaction 308,318 shares Direct holdings of the CFO following the September 21, 2026 sale

RSU vesting date September 18, 2026 Date RSUs vested, creating tax withholding obligation

Key Terms

restricted stock units, tax withholding obligations, Rule 10b5-1(c) trading plan

3 terms

restricted stock units financial

"arising in connection with the vesting of restricted stock units on September"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"sold ... to satisfy tax withholding obligations arising in connection"

Rule 10b5-1(c) trading plan regulatory

"These sales were effected pursuant to a pre-established Rule 10b5-1(c) trading plan"

A Rule 10b5-1(c) trading plan is a legally defined, pre-set schedule that lets company insiders automatically buy or sell stock at specified times or under set formulas when they are not in possession of undisclosed, sensitive information. Think of it like an automatic payment plan for trades: because the instructions are written in advance, trades under the plan help protect insiders from allegations of trading on secret information and give investors clearer expectations about when insiders will transact, which can affect liquidity and perceived transparency.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did SOPH report for its CFO George Cardoza?

SOPHiA GENETICS SA reported that its Chief Financial Officer, George Cardoza, sold 774 ordinary shares on September 21, 2026 at $8.33 per share, leaving him with 308,318 shares held directly after the transaction.

Why did the SOPH CFO sell 774 shares in this Form 4 filing?

The filing states the 774 shares were sold in the open market to satisfy tax withholding obligations arising from the vesting of restricted stock units on September 18, 2026, rather than as a discretionary sale of shares.

Was the SOPH CFO’s September 21, 2026 sale made under a Rule 10b5-1 plan?

Yes. The filing notes the sales were effected pursuant to a pre-established Rule 10b5-1(c) trading plan adopted by the reporting person and indicates they do not represent discretionary trades.

How many SOPH shares does the CFO hold after this reported sale?

After selling 774 ordinary shares, the Chief Financial Officer is reported as holding 308,318 shares of SOPHiA GENETICS SA directly following the transaction on September 21, 2026.

What price did the SOPH CFO receive per share in this transaction?

The reported transaction price was $8.33 per ordinary share for the 774 shares sold on September 21, 2026, characterized as a sale in the open market or a private transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/22/2026 - 04:03 PM Accepted by SEC EDGAR 09/22/2026 - 04:02 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CARDOZA GEORGE

(Last) (First) (Middle)

C/O SOPHIA GENETICS INC.

401 PARK DRIVE, FLOOR 5

(Street)

BOSTON MASSACHUSETTS 02215

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
SOPHiA GENETICS SA [ SOPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	09/21/2026		S		774(1)	D	$8.33	308,318	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on September 18, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1(c) trading plan adopted by the Reporting Person and do not represent discretionary trades.

Remarks:

	/s/ Elimara Brunetto as Attorney-in-Fact for George Cardoza	09/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)